We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

This study is currently recruiting participants.
Verified January 2017 by John Mascarenhas, Icahn School of Medicine at Mount Sinai
Sponsor:
ClinicalTrials.gov Identifier:
NCT02076191
First Posted: March 3, 2014
Last Update Posted: January 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Incyte Corporation
Information provided by (Responsible Party):
John Mascarenhas, Icahn School of Medicine at Mount Sinai
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2018
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)